- CHAIN have closed a financing round led by new investors, BGF and SynBioVen, alongside existing investor, UKI2S and strategic partner, Miyarisan Pharmaceutical.
- Investment will enable CHAIN to develop its CADD therapeutic platform and demonstrate its unique potential for use as an immune therapy in oncology.
- CHAIN will initially focus on immune therapies to treat Cervical, Oral and Pharyngeal cancers.
Nottingham, United Kingdom – 26 July 2023 – CHAIN Biotechnology Limited (‘CHAIN’, or ‘the Company’), has developed a unique proprietary, therapeutic approach based on engineering a probiotic strain of Clostridium to deliver oral vaccines and therapeutics. CHAIN’s Clostridium Assisted Drug Development platform (CADD) technology is a live therapeutic that employs a triple mode of action, incorporating mucosal and systemic immune responses alongside microbiome enhancement, and is delivered via highly stable, robust endospores that allow targeted, controllable therapeutic action.
CHAIN’s platform is already in development to deliver prophylactic vaccines and this funding round will enable CHAIN to focus on using its unique platform as a treatment for major solid tumour cancers.
The round was led by new investors, Business Growth Fund (BGF), one of the largest and most experienced investors in the UK and Ireland, and venture capital investment group SynBioVen, who specialize in backing synthetic biology-based products, together with strategic investor and partner Miyarisan Pharmaceuticals and existing investor, UKI2S.
Matthew Duchars, CEO of CHAIN, said: “This funding is instrumental in enabling CHAIN to advance its platform in the field of immune-oncology. CHAIN’s CADD system has huge potential to provide an effective and easy to administer therapy in this field. We are very excited to welcome our new investors BGF and SynBioVen who, together with Miyarisan and UKI2S, have enabled us to move forward with this exciting stage in CADD’s development.”
Tim Rea, head of early-stage investments at BGF, said: “CHAIN is a leading light in the field of microbiome medicine, offering a highly differentiated and patent-protected platform which enables safe and effective oral drug delivery for a range of conditions. We have been consistently impressed by the progress CHAIN has made to date and believe it is now in an ideal position to capitalise on the vast potential of its ground-breaking technology.”
For further information, please contact:
CHAIN Biotechnology
Matthew Duchars, Chief Executive Officer
Phone: +44 (0) 7494 260812
Email: matthew.duchars@chainbiotech.com